Exciting News! Our Gainesville Office has moved to Bristow – 9450 Innovation Drive, Manassas, VA 20110. Same great providers and care team, same exceptional care, new, larger space to better serve our patients.
A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG). Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
